Research Projects

Proposal Date

Project Title

Principal Investigator(s)

Status

09/01/2011

Risk factors by aggressiveness

Fortner

Published

09/01/2011

Risk factors by histologic subtype

Wentzensen

Published

09/01/2011

Risk factors by tumor dominance

Tworoger, Arslan, Visvanathan, Patel, Wentzensen

Published

09/01/2011

Risk prediction modeling accounting for tumor subtype

Tworoger, Arslan, Visvanathan, Patel, Wentzensen

Ongoing

02/08/2012

Aspirin, non-aspirin NSAID, acetaminophen use and ovarian cancer risk

Trabert

Published

02/08/2012

Endometriosis and histologic subtypes of ovarian cancer

Trabert

Published

09/01/2012

Base risk prediction model in US Caucasian women (with OCAC)

Tworoger, Schildkraut, Iversen

Ongoing

10/01/2012

Androgens and ovarian cancer risk

Kaaks

Published

10/01/2012

IGF-I and risk of ovarian cancer risk

Kaaks

Published

11/05/2012

Inflammation-related exposures and risk of ovarian cancer, CRP

Poole

Published

06/01/2013

OncoArray (GWAS)

Wentzensen, Tworoger

Ongoing

11/03/2014

Risk factors by primary site

Rice, Schouten, Fortner

Published

05/14/2015

Hypertension, antihypertensive medications, and ovarian cancer: OC3

Tworoger

Ongoing

08/03/2015

Exposure-wide association study of high-grade serous ovarian cancer: OC3

Trabert, Tworoger

Ongoing

09/22/2015

Lifetime ovulatory cycles and ovarian cancer risk in OC3

Trabert

Published

09/07/2016

Identification of immune-proteomic markers for ovarian cancer detection

Kaaks

Ongoing

09/14/2016

Coffee, tea, and caffeine consumption and ovarian cancer risk

Harris

Ongoing

10/20/2016

Epigenetic risk marker for ovarian cancer

Flanagan

Ongoing

12/16/2016

Diabetes and ovarian cancer risk

Harris

Ongoing

06/16/2017

Genetic predictors of CA125

Terry

Ongoing

11/01/2017

Understanding racial and ethnic differences in epithelial ovarian cancer risk and survival

Merritt

Ongoing

01/16/2018

Talc and gynecologic cancer risk (An OC3 analysis)

O'Brien, Wentzensen, Sandler

Published

05/14/2018

Pre- and post-diagnosis analgesic use and ovarian cancer survival

Merritt

Ongoing

09/19/2018

Making the CASE: Chemopreventive Use of Aspirin for Ovarian Cancer - Integrating Epidemiological Data to Evaluate Population Subgroups and Tumor Expression

Trabert

Ongoing

01/14/2019

Risk factors among women with endometriosis

Harris

Ongoing

04/11/2019

IUD use and ovarian cancer risk

Terry

Ongoing

07/09/2019

Breastfeeding and ovarian cancer risk and survival

Sasamoto, Terry

Ongoing

02/11/2020

Hormone therapy and risk

O'Brien, Harris, Sandler, Tworoger

Ongoing

05/10/2021

Statins and ovarian cancer risk

Zeleznik

Ongoing

08/10/2021

Hormone therapy and survival

Sasamoto

Ongoing

08/19/2021

Antibodies against chlamydia trachomatis and other infections and ovarian cancer histotypes

Trabert, Fortner

Ongoing

11/16/2021

The association of diseases impacting kidney function with ovarian cancer risk

Hathaway

Ongoing


Publications

11. Townsend MK, Trabert B, Fortner RT, Arslan AA, Buring JE, Carter BD, Giles GG, Irvin SR, Jones ME, Kaaks R, Kirsh VA, Knutsen SF, Koh WP, Lacey JV, Langseth H, Larsson SC, Lee IM, Martínez ME, Merritt MA, Milne RL, O'Brien KM, Orlich MJ, Palmer JR, Patel AV, Peters U, Poynter JN, Robien K, Rohan TE, Rosenberg L, Sandin S, Sandler DP, Schouten LJ, Setiawan VW, Swerdlow AJ, Ursin G, van den Brandt PA, Visvanathan K, Weiderpass E, Wolk A, Yuan JM, Zeleniuch-Jacquotte A, Tworoger SS, Wentzensen N. Cohort Profile: The Ovarian Cancer Cohort Consortium (OC). Int J Epidemiol. 2021 Oct 15:dyab211. doi: 10.1093/ije/dyab211.

 

10. Fortner RT, Rice MS, Knutsen SF, Orlich MJ, Visvanathan K, Patel AV, Gaudet MM, Tjønneland A, Kvaskoff M, Kaaks R, Trichopolou A, Pala V, Onland-Moret NC, Gram IT, Amiano P, Idahl A, Allen NE, Weiderpass E, Poynter JN, Robien K, Giles GG, Milne RL, Setiawan VW, Merritt MA, van den Brandt PA, Zeleniuch-Jacquotte A, Arslan AA, O'Brien KM, Sandler DP, Wolk A, Håkansson N, Harris HR, Trabert B, Wentzensen N, Tworoger SS, Schouten LJ. Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):2010-2018. doi:10.1158/1055-9965.EPI-20-0354 

 

9.  Trabert B, Tworoger SS, O'Brien KM, Townsend MK, Fortner RT, Iversen ES, Hartge P, White E, Amiano P, Arslan AA, Bernstein L, Brinton LA, Buring JE, Dossus L, Fraser GE, Gaudet MM, Giles GG, Gram IT, Harris HR, Bolton JH, Idahl A, Jones ME, Kaaks R, Kirsh VA, Knutsen SF, Kvaskoff M, Lacey JV, Lee IM, Milne RL, Onland-Moret NC, Overvad K, Patel AV, Peters U, Poynter JN, Riboli E, Robien K, Rohan TE, Sandler DP, Schairer C, Schouten LJ, Setiawan VW, Swerdlow AJ, Travis RC, Trichopoulou A, van den Brandt PA, Visvanathan K, Wilkens LR, Wolk A, Zeleniuch-Jacquotte A, Wentzensen N; Ovarian Cancer Cohort Consortium (OC3). The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Res. 2020 Mar 1;80(5):1210-1218. doi:10.1158/0008-5472.CAN-19-2850 

 

8.  O'Brien KM, Tworoger SS, Harris HR, Anderson GL, Weinberg CR, Trabert B, Kaunitz AM, D'Aloisio AA, Sandler DP, Wentzensen N. Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. JAMA. 2020 Jan 7;323(1):49-59. doi:10.1001/jama.2019.20079

 

7.  Huang T, Townsend MK, Wentzensen N, Trabert B, White E, Arslan AA, Weiderpass E, Buring JE, Clendenen TV, Giles GG, Lee IM, Milne RL, Onland-Moret NC, Peters U, Sandler DP, Schouten LJ, van den Brandt PA, Wolk A, Zeleniuch-Jacquotte A, Tworoger SS. Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3). Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):200-207. doi:10.1158/1055-9965.EPI-19-0734

 

6.  Peres LC, Mallen AR, Townsend MK, Poole EM, Trabert B, Allen NE, Arslan AA, Dossus L, Fortner RT, Gram IT, Hartge P, Idahl A, Kaaks R, Kvaskoff M, Magliocco AM, Merritt MA, Quirós JR, Tjonneland A, Trichopoulou A, Tumino R, van Gils CH, Visvanathan K, Wentzensen N, Zeleniuch-Jacquotte A, Tworoger SS. (2019). High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium. Cancer Res. 2019 Oct 15;79(20):5442-5451. doi:10.1158/0008-5472.CAN-19-1554

 

5.  Fortner RT, Poole EM, Wentzensen NA, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Clendenen TV, Fournier A, Fraser G, Gapstur SM, Gaudet MM, Giles GG, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Kaaks R, Kirsh VA, Knutsen S, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Milne RL, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sánchez MJ, Schairer C, Schouten LJ, Tjonneland A, Townsend MK, Travis RC, Trichopoulou A, van den Brandt PA, Vineis P, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS. Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium. Int J Cancer. 2019 Jul 1;145(1):58-69. doi:10.1002/ijc.32075

 

4.  Trabert B, Poole EM, White E, Visvanathan K, Adami HO, Anderson GL, Brasky TM, Brinton LA, Fortner RT, Gaudet M, Hartge P, Hoffman-Bolton J, Jones M, Lacey JV, Larsson SC, Mackenzie GG, Schouten LJ, Sandler DP, O'Brien K, Patel AV, Peters U, Prizment A, Robien K, Setiawan VW, Swerdlow A, van den Brandt PA, Weiderpass E, Wilkens LR, Wolk A, Wentzensen N, Tworoger SS; Ovarian Cancer Cohort Consortium (OC3). Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. J Natl Cancer Inst. 2019 Feb 1;111(2):137-145. doi:10.1093/jnci/djy100 

 

3. Ose J, Poole EM, Schock H, Lehtinen M, Arslan AA, Zeleniuch-Jacquotte A, Visvanathan K, Helzlsouer K, Buring JE, Lee IM, Tjønneland A, Dossus L, Trichopoulou A, Masala G, Onland-Moret NC, Weiderpass E, Duell EJ, Idahl A, Travis RC, Rinaldi S, Merritt MA, Trabert B, Wentzensen N, Tworoger SS, Kaaks R, Fortner RT. Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. Cancer Res. 2017 Jul 15;77(14):3951-3960. doi:10.1158/0008-5472.CAN-16-3322

 

2.  Ose J, Schock H, Poole EM, Lehtinen M, Visvanathan K, Helzlsouer K, Buring JE, Lee IM, Tjønneland A, Boutron-Ruault MC, Trichopoulou A, Mattiello A, Onland-Moret NC, Weiderpass E, Sánchez MJ, Idahl A, Travis RC, Rinaldi S, Merritt MA, Wentzensen N, Tworoger SS, Kaaks R, Fortner RT. Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. Cancer Causes Control. 2017 May;28(5):429-435. doi:10.1007/s10552-017-0852-8

 

1.  Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjöholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt PA, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016 Aug 20;34(24):2888-2898. doi:10.1200/JCO.2016.66.8178